Zydus Cadila receives final approval from USFDA to market Memantine Hydrochloride tablets
DSIJ Intelligence / 12 Jul 2017
At Rs 517.75, Cadila Healthcare was trading up by Rs 0.25 or 0.05 at 1113 hours on Wednesday, on the BSE. The stock had hit an intraday high of Rs 524.70.
In a BSE filing on Wednesday, Zydus Cadila said that the company has received the final approval from the USFDA to market Memantine Hydrochloride tablets USP, 5 mg and 10 mg.
The drug is used for the treatment of moderate to severe dementia (Alzheimer’s type) and will be produced at the group’s facility in Moraiya, Ahmedabad.
At Rs 517.75, Cadila Healthcare was trading up by Rs 0.25 or 0.05 at 1113 hours on Wednesday, on the BSE. The stock had hit an intraday high of Rs 524.70.
The group now has more than 120 approvals and so far, it has filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.